Pharmaceutical Intermediates Market Size, Growth, Trends, Forecast 2023-2032
The global pharmaceutical intermediates market size was estimated at around USD 2.38 billion in 2022 and it is projected to hit around USD 4.74 billion by 2032, growing at a CAGR of 7.14% from 2023 to 2032.
Rise in prevalence of chronic diseases, focus on research & development by key players and business strategies adopted by key players are the key factors projected to fuel the growth of the global pharmaceutical intermediates market during the forecast period.
The demand for pharmaceutical intermediates majorly depends on the rise in the demand for essential drugs to treat chronic diseases. The growing prevalence of contagious diseases, principally in Southeast Asia, is likely to fuel the demand for APIs in the following years, ultimately propelling the pharmaceutical intermediates market. Moreover, advancements in technologies such as high throughput, bioinformatics, and combinatorial chemistry for better drug candidate identification are increasing the demand for pharmaceutical intermediates for research purposes. Hence, owing to rising production and research exercises in the pharmaceutical industry, the usage of pharmaceutical intermediates is expected to witness a constant growth during the projected period.
Focus on Research & Development to Propel Market
The development of innovative and effective health products for humans has increased in the past few decades. Key players are gearing up to introduce new drugs in the market. The research-based pharmaceutical industry can play a critical role in restoring growth and ensuring future competitiveness in an advancing global economy. The high investment in R&D capabilities and infrastructure by the industries and governments alike is anticipated to create lucrative opportunities in the global pharmaceutical intermediates market. The rising R&D pipeline of India-based companies presents significant in-licensing opportunities for global companies.
Why pharmaceutical intermediates?
Pharmaceutical intermediates are drugs used as raw materials in the production of bulk drugs. Moreover, they are widely used to refer to a material created during the synthesis of an active pharmaceutical ingredient (API) before the processing of becoming an API. Pharmaceutical intermediates are usually formed using high-grade raw materials. These intermediates are widely used in the pharmaceutical and cosmetic industries. The rising demand in these industries is expanding the global pharmaceutical intermediates market. Pharmaceutical intermediates are popularly used for research and development in the pharmaceutical industry. The pharmaceutical intermediates are increasingly being produced using raw materials such as coal tar or petroleum to manufacture pesticides, pharmaceuticals, resins, additives, plasticizers, etc. However, several intermediates can be produced in organic synthesis, and be used in creating various drugs and products.
Report Scope
In terms of product, the global pharmaceutical intermediates market has been bifurcated into bulk drug intermediate and custom intermediate. The bulk drug intermediate segment has been split into chiral intermediate and achiral intermediate.
Based on application, the global pharmaceutical intermediates market has been segregated into cardiology, oncology, endocrinology, infectious diseases, orthopedics, neurology, gastroenterology, dermatology, inflammatory & pain management, ophthalmology, and others. Changes in lifestyle i.e., increase in consumption of tobacco and burden of cancer fuels the growth of the oncology segment.
In terms of end user, the global pharmaceutical intermediates market has been divided into pharmaceutical & biotechnology companies and CROs & CMOs. The fragmented structure of the CRO industry has led to an increase in strategic alliances, acquisitions, joint ventures, and other partnership deals as companies attempt to expand their service offerings and geographical presence.
In terms of region, the North America is expected to account for a significant share of the global pharmaceutical intermediates market during the forecast period. The growth of the pharmaceutical intermediates market in the region can be attributed to rise in access to healthcare and increase in incidence of chronic diseases. According to the World Health Organization, stroke, diabetes mellitus, COPD, and lower respiratory diseases were the top causes of death in 2020.
The market in Asia Pacific is likely to expand at a high CAGR from 2023 to 2032. The increase in the geriatric population is projected to boost the market in the region.
Key Players
The report provides profiles of leading players operating in the global pharmaceutical intermediates market. These include BASF SE, Lonza Group, Evonik Industries AG, Cambrex Corporation, DSM, Aceto, Albemarle Corporation, Vertellus, Chemcon Speciality Chemicals Ltd., Chiracon GmbH, and A. R. Life Sciences Private Limited.
Market Segmentation
By Product
By Application
By End User
By Region
This report focuses on pharmaceutical intermediates market includes crucial information on market share, market size, and growth rate for the forecast period 2023 to 2032 at the global level, regional level and company level. From a global perspective, this report represents overall pharmaceutical intermediates market size by analyzing historical data and future prospect. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics. The study includes drivers and restraints of the global pharmaceutical intermediates market.
The research not only conducts forecasts in terms of value, but also evaluates the market on the basis of essential parameters, such as Year-on-Year (Y-o-Y) growth. This helps providers to recognize the future opportunities as well predictability of the market.
In order to understand and assess opportunities in this market, the report is categorically divided into five key sections on the basis of segments. The report analyzes the global market in terms of value (US$ dollers) and volume (Million Units).
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2023 to 2032. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the pharmaceutical intermediates market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the pharmaceutical intermediates market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Pharmaceutical intermediates market.
Market Segments: This part of the report discusses about product, application and other segments of the pharmaceutical intermediates market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
Regional Analysis
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2023 to 2032. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global pharmaceutical intermediates market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the pharmaceutical intermediates market.
The report includes country-wise and region-wise market size for the period 2023-2032. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2023-2032.
Competitive Landscape and Market Share Analysis
The pharmaceutical intermediates market competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, pharmaceutical intermediates sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2017-2020, this study provides the pharmaceutical intermediates sales, revenue and market share for each player covered in this report.
Research Methodology
The research methodology adopted by analysts for compiling the global pharmaceutical intermediates market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global pharmaceutical intermediates market.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Pharmaceutical Intermediates Market, By Product
7.1. Pharmaceutical Intermediates Market, by Product, 2021-2030
7.1.1. Bulk Drug Intermediate
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Custom Intermediate
7.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Pharmaceutical Intermediates Market, By Application
8.1. Pharmaceutical Intermediates Market, by Application, 2021-2030
8.1.1. Cardiology
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Oncology
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Endocrinology
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Infectious Diseases
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Orthopedics
8.1.5.1. Market Revenue and Forecast (2016-2030)
8.1.6. Neurology
8.1.6.1. Market Revenue and Forecast (2016-2030)
8.1.7. Gastroenterology
8.1.7.1. Market Revenue and Forecast (2016-2030)
8.1.8. Dermatology
8.1.8.1. Market Revenue and Forecast (2016-2030)
8.1.9. Inflammatory & Pain Management
8.1.9.1. Market Revenue and Forecast (2016-2030)
8.1.10. Ophthalmology
8.1.10.1. Market Revenue and Forecast (2016-2030)
8.1.11. Others
8.1.11.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Pharmaceutical Intermediates Market, By End User
9.1. Pharmaceutical Intermediates Market, by End User, 2021-2030
9.1.1. Pharmaceutical & Biotechnology Companies
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. CROs & CMOs
9.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 10.Global Pharmaceutical Intermediates Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2016-2030)
10.1.2. Market Revenue and Forecast, by Application (2016-2030)
10.1.3. Market Revenue and Forecast, by End User (2016-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.1.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.1.5.3. Market Revenue and Forecast, by End User (2016-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2016-2030)
10.2.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.3. Market Revenue and Forecast, by End User (2016-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.5.3. Market Revenue and Forecast, by End User (2016-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2016-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.6.3. Market Revenue and Forecast, by End User (2016-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2016-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.7.3. Market Revenue and Forecast, by End User (2016-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2016-2030)
10.3.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.3. Market Revenue and Forecast, by End User (2016-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.5.3. Market Revenue and Forecast, by End User (2016-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2016-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.6.3. Market Revenue and Forecast, by End User (2016-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2016-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.7.3. Market Revenue and Forecast, by End User (2016-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.5.3. Market Revenue and Forecast, by End User (2016-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2016-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.6.3. Market Revenue and Forecast, by End User (2016-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2016-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.7.3. Market Revenue and Forecast, by End User (2016-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.5.3. Market Revenue and Forecast, by End User (2016-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2016-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.5.4.3. Market Revenue and Forecast, by End User (2016-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2016-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.5.5.3. Market Revenue and Forecast, by End User (2016-2030)
Chapter 11. Company Profiles
11.1. BASF SE
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Lonza Group
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Evonik Industries AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cambrex Corporation
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. DSM
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Aceto
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Albemarle Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Vertellus
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Chemcon Speciality Chemicals Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Chiracon GmbH
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers